Figure 2.

Diabetes onset is not altered in NOD mice immunized with a CVB1–6 vaccine. A–C: Female NOD mice (mean age, 5.7 weeks; range, 4.9–7.1 weeks) were left untreated (n = 10), mock-vaccinated (n = 15), or vaccinated (n = 14) with the CVB1–6 vaccine by interscapular injection on days 0 and 21 (n = 6 for buffer, n = 10 for CVB1–6 vaccine) or days 0, 21, and 35 (n = 9 for buffer, n = 4 for CVB1–6 vaccine). A: Average neutralizing antibody titers in the serum of CVB1–6 vaccinated mice against the six CVB serotypes on day 42 after the first vaccination dose. Sera from untreated and mock-vaccinated mice had no neutralizing capacity. Shown are the mean ± SD virus-neutralizing antibody titers, with individual mice represented by a single symbol. The blue symbols represent virus-neutralizing antibody titer data that were also previously published (13). Cumulative diabetes incidence (B) and average age at diabetes onset (C) in the three groups. The dotted lines in B and C show the average age at vaccination. The mean ± SD age at diabetes onset is shown in C, and the ages at which individual animals developed diabetes are displayed as single symbols. No statistically significant differences were found between the groups using the Gehan-Breslow-Wilcoxon test (B) or one-way ANOVA with the Tukey multiple comparison test (C).